Teva A, Porrozzi R, Oliveira-Neto M P, Grimaldi G Júnior
Department of Immunology, Institute Oswaldo Cruz, FIOCRUZ, Av. Brasil 4365, Rio de Janeiro RJ, CEP 21045-900, Brazil.
J Parasitol. 2005 Aug;91(4):976-8. doi: 10.1645/GE-3486RN.1.
The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. The therapeutic responses in experimental animals to either a low dose (5 mg/kg body wt/day for 28 days) or a routine dose (20 mg/kg/day for 28 days) of pentavalent antimony were similar to those reported in the human disease. Primates were cured of their lesions after treatment, but with cryptic parasitism and/or relapse. The rhesus model of L. (V.) braziliensis cutaneous leishmaniasis therefore provides an additional resource for preclinical trials with newer drugs.
在患有急性和慢性巴西利什曼原虫(维安尼亚亚种)皮肤感染的恒河猴群体中,对参比药物葡甲胺锑酸盐(葡酸锑钠)的抗利什曼原虫疗效进行了评估。实验动物对低剂量(5毫克/千克体重/天,持续28天)或常规剂量(20毫克/千克/天,持续28天)五价锑的治疗反应与人类疾病中报告的反应相似。灵长类动物在治疗后病变得到治愈,但存在隐匿性寄生和/或复发情况。因此,巴西利什曼原虫(维安尼亚亚种)皮肤利什曼病的恒河猴模型为新型药物的临床前试验提供了额外资源。